Business Context and Reporting Period
This Form 8-K, filed on August 21, 2023, reports material events for Skye Bioscience, Inc. (Skye) occurring on August 15 and August 18, 2023. The primary event is the completion of a merger with Bird Rock Bio, Inc. (Bird Rock), alongside a concurrent private placement financing and the issuance of a secured convertible note. The filing also details the posting of an appeal bond related to pending litigation.
Key Financial Metrics and Capital Structure
- Merger Consideration: Skye issued approximately 968.97 million shares of common stock to former Bird Rock stockholders, valued at approximately $20.0 million based on a 60-day volume-weighted average price.
- Private Placement (PIPE): Skye raised $12.0 million by selling 581.38 million shares of common stock and accompanying warrants to purchase an equal number of shares at $0.02064041 per share.
- Debt Financing: Skye issued a secured convertible promissory note to MFDI, LLC in the principal amount of $5.0 million, bearing 10.0% annual interest, alongside a warrant to purchase 85.0 million shares.
- Post-Transaction Ownership: Immediately following the transactions, approximately 3.08 billion shares were outstanding. Former Bird Rock equity holders owned ~31.4%, PIPE Investors owned ~37.0%, and pre-merger Skye equity holders owned ~31.6%.
- Liquidity and Obligations: The company posted an appeal bond of $9,080,201.63 secured by an irrevocable letter of credit from Fifth Third Bank.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements (revenue, profit, or cash flow) for the current period versus the prior period. However, the capital structure underwent a material change:
- Equity Dilution: The share count increased significantly to approximately 3.08 billion shares due to the merger and PIPE financing.
- Debt Increase: The company incurred a new $5.0 million secured debt obligation.
- Corporate Structure: Bird Rock Bio, Inc. became a wholly-owned subsidiary of Skye Bioscience, Inc.
Guidance, Outlook, Risks, and Unusual Items
- Management Commentary: The company intends to effect a reverse stock split of its outstanding shares of common stock. A conference call was held on August 21, 2023, to discuss the transactions.
- Lock-up Agreements: Certain Bird Rock stockholders, Skye stockholders, directors, officers, and Investors are subject to a one-year lock-up on the sale or transfer of shares held as of the closing.
- Legal Contingency: The company is appealing a jury verdict in the case Wendy Cunning vs. Skye Bioscience, Inc. The appeal bond of approximately $9.08 million was posted on August 18, 2023, to stay enforcement of the judgment pending appeal.
- Debt Covenants: The $5.0 million note to MFDI is secured by the company's real property in Canada and matures in 12 months or earlier if the appellate bond face value is reduced below $4.28 million.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks and uncertainties, noting that future performance is not assured.
Investor Verification Checklist
- Verify the exact terms of the reverse stock split, including the ratio and effective date, as only the intention was disclosed.
- Review the full text of the Merger Agreement (Exhibit 2.1) and Securities Purchase Agreement (Exhibit 10.1) for specific covenants and limitations on future equity sales.
- Monitor the status of the Wendy Cunning litigation and the potential impact of the $9.08 million appeal bond on liquidity.
- Confirm the registration status of the PIPE shares and warrants, as they were sold under exemptions and may require a resale registration statement within 180 days.
- Assess the impact of the 10% interest rate and conversion terms of the MFDI note on future earnings and equity dilution.